Montefiore Medical Center Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial
2014
NCT02127073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Associate Professor in The Leo M. Davidoff Department of Neurological Surgery at Montefiore | Montefiore Health System and Albert Einstein College of Medicine, Newyork, United States of America (USA)

Active Ingredients

Drugs in Phase 4 Trials (3)

13-cis-retinoic Acid (1 trial)

retinoic acid (1 trial)

vitamin d (1 trial)

Drugs in Phase 1 Trials (1)

oxytocin (syntocinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Ductal (Phase 1)

Carcinoma in Situ (Phase 1)

Carcinoma, Intraductal, Noninfiltrating (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4